# Anaphylaxis and Shock

## Case Protocol 4 – **Anaphylactic shock**

*A 66-year-old woman was brought by ambulance to the Emergency Department in extremis. She had obvious upper airway obstruction, with tachypnoea, inspiratory and expiratory stridor, and bilateral rhonchi. She was tachycardic, hypotensive, pale, drowsy and incoherent. Her face, eyes and tongue were swollen and her skin showed widespread urticaria.*

[](data:image/png;base64,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)

*The patient was intubated and ventilated, treated with adrenaline, intravenous fluids, glucocorticoids and antihistamine. She was then admitted to the intensive care unit. Results of initial investigations are outlined below.*

![Screenshot 2025-06-12 at 7.41.45 PM.png](Anaphylaxis%20and%20Shock%201300acf2446a8189a6deea617f20d5c4/Screenshot_2025-06-12_at_7.41.45_PM.png)

![Screenshot 2025-06-12 at 7.41.56 PM.png](Anaphylaxis%20and%20Shock%201300acf2446a8189a6deea617f20d5c4/Screenshot_2025-06-12_at_7.41.56_PM.png)

![Screenshot 2025-06-12 at 7.42.05 PM.png](Anaphylaxis%20and%20Shock%201300acf2446a8189a6deea617f20d5c4/Screenshot_2025-06-12_at_7.42.05_PM.png)

- Definition of anaphylaxis
    
    Severe Type 1 hypersensitivity r/c (allergic reaction)
    
    life-threatening and systemic manifestation 
    
    resulting from basophil or IgE-mediated mast cell degranulation (immune-mediated)
    
    anaphylactoid = direct nonimmune-mediated activation of mast cells OR complement cascade (non-allergic reaction/pseudoallergy)
    
    otherwise clinically similar to anaphylaxis 
    
    eg: contrast, worm (parasitic) antigens, anaesthesia 
    
    - Jason definition
        - A multi-system severe allergic reaction characterised by acute onset of cardiovascular or respiratory systems often associated with typical skin features (urticaria, angioedema, flushing) and/or persistent severe GIT symptoms
- Clinical features of anaphylaxis
    - Hypotension
        - Widespread vasodilation and increased vascular resistance → distributive shock
    - Drowsiness
        - Decreased cerebral perfusion secondary to hypotension
    - Tachycardia and tachypnoea
        - Increased sympathetic outflow (baroreceptors detect low perfusion pressure in aortic arch and carotid sinus)
            - Chemoreceptors detect increased CO2
    - Stridor, inability to speak, facial oedema
        - Angioedema secondary to increased capillary permeability (swelling of deeper subcutaneous structures)
    - Wheeze
        - Bronchospasm → smooth muscle contraction stimulated by histamine and leukotrienes
            - May a direct response to vagal irritation
    - Urticaria and pruritus
        - Increased vascular permeability of skin (urticaria) and nerve irritation (pruritus)
- Diagnostic criteria for anaphylaxis
    - Clinical diagnosis supported by any one of the following three criteria
    1. Acute onset of illness (mins to hours) with involvement of the skin, mucosal tissue or both (urticaria, pruritus, flushing, angioedema)
        1. With respiratory compromise (dyspnoea, wheeze-bronchospasm, stridor)
        2. Reduced BP or associated symptoms of end organ damage
    2. 2+ of the following which occur rapidly after exposure to a likely allergen (mins to hours)
        1. Involvement of the skin or mucosal tissue
        2. Respiratory compromise
        3. Reduced BP or associated symptoms
        4. Persistent GIT symptoms (cramping abdominal pain, vomiting)
    3. Reduced BP after exposure to a known allergen for that patient (mins to several hours)
- Investigative approach to anaphylaxis
    - Investigations during the acute phase
        - Definitive
            - Primary survey - concurrent assessment and management (emergency)
            - Bedside
                - Vital signs
            - Labs
                - Serum tryptase
                    - Proteinase released during mast cell activation
                    - Differentiates between IgE-mediated anaphylaxis v. other
                    - Not available on an emergency basis (assay takes several hours) but important to assist retrospective confirmation of anaphylaxis
                    - Obtain 1-3 hours after onset, compare with baseline 24h post-resolution
                - Plasma histamine
        - Ancillary
            - Bedside
                - Blood gas
                - ECG
            - Labs
                - FBC (eosinophilia)
                - UEC, LFT (end organ dysfunction)
            - Imaging
                - CXR to exclude differentials
    - Investigations to confirm allergy and identify triggers
        - Serum allergen-specific IgE assay (formerly RAST - radioallergosorbent testing)
            - Detects specific IgE antibodies
            - No risk of allergic reaction during testing
        - Skin prick test
            - Cease anti-histamines prior to the test
            - Should be performed by an allergy specialist with resuscitation equipment on hand
        - Allergen-specific challenge tests (only if cause in doubt with trained medical staff)
            - Food
            - Non-specific (cold, exercise)
- Approach to assessment and management of anaphylaxis
    - Initial management
        - Remove causative agent (if known)
        - Call for help - medical emergency
        - Establish continuous monitoring, IV access
        - Primary survey
            - Ax airway - ?patent(intubate if compromised)
            - Supplemental O2 as needed
            - Fluid resuscitation if hypotensive
        - Position
            - If prominent upper airway swelling → patient upright, leaning forward
            - Patient supine with lower extremities elevated
                - If vomiting → patient semirecumbent
    - Definitive management (at earliest opportunity)
        - IM adrenaline (0.5mL of 1:1000 adrenaline)
            - Recommended dose is 0.01mg/kg (0.3mL for 25-50kg, 0.5mL for > 50kg)
            - Repeat every 5 mins as required until response achieved
        - If patient does not respond
            - Consider adrenaline infusion (requires ED/ICU expertise for monitoring)
                - 1mL of 1:1000 adrenaline in 1L normal saline at 5mL/kg/hr
                - Titrate to response and monitor
            - If refractory and adrenaline resistant - can administer IV glucagon bolus to bypass adrenergic receptors
    - Secondary treatment (adjunctive therapy after initial resus measures given + once px stabilised)
        - Antihistamines (manage urticaria and itch - not URT symptoms)
            - Diphenhydramine (H1 antagonist) IV (Q4h)
            - Discharge with 3 days PO antihistamines
        - Bronchodilators (inhaled salbutamol) if bronchospasm is not responsive to adrenaline
        - Corticosteroids may prevent biphasic reaction (limited evidence)
            - IV methylprednisone 125mg
            - Discharge with 5 days oral prednisone (patients with significant bronchospasm or known respiratory disease)
    - Discharge planning
        - Monitor for 6-8 hours
            - Px must be supervised up to 48h (due to biphasic reaction)
            - F/U w/ GP w/in time period
            - Referral to immunologist for allergen testing if first presentation
        - Counselling on allergen avoidance
        - Anaphylaxis action plan and at least one adrenaline autoinjector
- How would you conduct a primary survey
    - Airway → patent
        - Ax
            - Ability to speak
            - Observe: noisy breathing (stridor, stertor, gurgling, wheeze), potential obstructions, ability to maintain airway (LoC)
        - Management
            - C-spine stabilisation (hard collar, manual suction, forceps)
                - Jaw thrust if unable to move head
            - Basic airway manoeuvres (head tilt, chin lift, jaw thrust)
                - Insert oropharyngeal airway (Guedel) or nasopharyngeal airway as needed
            - Suction (Yankauer)
            - Supraglottic airways (LMA + bite block)
            - Definitive airway (endotracheal tube, nasotracheal tube, cricothyroidotomy)
    - Breathing → look, feel, hear (rise + fall, air on cheek/skin, breath sounds)
        - Ax
            - Evidence of respiratory distress and work of breathing
                - Chest expansion, added breath sounds, air entry
            - Vitals (SpO2, RR)
            - Blood gas
        - Management
            - Sit patient upright if possible
            - Supplemental O2 (aim > 94%)
                - Nasal prongs
                - Hudson mask or Venturi mask
                - Non-rebreather
            - Assisted ventilation
                - NIV (CPAP, BiPAP)
    - Circulation
        - Ax
            - Vitals (HR, BP, ECG)
            - Cardiac ausculatation
            - Signs of perfusion (CRT, distal temperature and pulses)
        - Management
            - Raise legs?
            - Chest compressions and defibrillaton
            - 2x large bore (14-16g) access for blood products or fluids
            - Medications
                - Vasopressors (vasopressin, metaraminol)
                - Adrenaline
                - Inotropes (dobutamine)
    - Disability
        - GCS
        - Pupils
        - Focal or lateralising neurological signs
    - Exposure
        - Temp.
        - Wounds, rashes, external haemorrhage
    - Glucose
        - BSL - manage with IV dextrose
- Pharmacology of anaphylaxis
    - Adrenaline
        - Non-selective adrenergic agonist
        - MOA
            - Natural catecholamine prod. in adrenal medulla acts on adrenergic receptors (B>a)
            - A1 (vasoconstriction)
                - Increased TPR and BP → decreased mucosal oedema
            - B1 (cardiac inotropy and chronotropy)
                - Increased CO and BP
            - B2 (bronchodilation)
            - May stabilise mast cells directly
        - AEs
            - Sympathomimetic (anxiety, restlessness, dizziness, arrhythmias, palpitations, tremor, hypertension)
    - Antihistamines
        - Diphenhydramine (H1 receptor antagonist)
            - MOA: block histamine receptors in smooth muscle, endothelial and immune (mast) cells
                - Decreased smooth muscle spasm (bronchospasm)
                - Decreased endothelial vascular permeability and vasodilation
- Pathophysiology of anaphylaxis
    - Sensitisation
        - Initial exposure to allergen - presented by APCs (dendritic cells, B cells) via MHC-II to CD4 T cells
            - Promotes differentiation to TH2 (helper) cells
            - TH2 cells migrate to B cells in germinal centre of lymph nodes and induce:
                - Class switching to IgE
                - Somatic hypermutation (increased antibody specificity)
            - Mediated by IL-4
        - Circulating IgE binds to mast cells in peripheral tissue = Priming
    - Early phase (acute) response
        - On subsequent exposure to the allergen
            - Antigen binds to specific IgE on mast cells and cross-links receptors
            - Cause degranulation of histamine, PGs and other inflamm mediators
        - Mediate acute effects
            - Bronchoconstriction
            - Vasodilation and increased vascular permeability
    - Late phase (delayed) response
        - Characteristic leukocyte infiltration of tissues (eosinophils from blood) and ongoing mucosal inflammation
- Causes of anaphylaxis
    - Allergic (IgE-mediated) (requires second exposure for mast cell sensitisation)
        - Foods
        - Insect stings or bites
        - Inhalants
        - Iatrogenic (medications, latex, blood products)
    - Non-IgE mediated
        - Complement mediated
            - Hereditary angioedema
                - Multiple aetiologies but most known is a deficiency of C1-inhibitor
                    - Protease which normally inhibits the complement system and prevents spontaneous activation
                    - Deficiency = excessive bradykinin production (vasodilation, increased vascular permeability)
            - Serum sickness
                - A type III hypersensitivity reaction often as a complication of anti-toxin or anti-venom administration
                    - Products with animal proteins (equine anti-spider venom, equine or bovine anti-rabies)
                - Pathophysiology
                    - Formation of antibodies against the animal protein
                        - Deposition of antibody-antigen complexes in tissue → complement activation → tissue damage and systemic inflammation
                - Clinical presentation
                    - Fever, rash, polyarthralgias
                    - Tends to occur 5-10 days post-exposure (seroconversion)
            - Transfusion reactions
        - Non-immunological
            - Direct mast cell degranulation due to radiocontrast agents, opioids, temperature, exercise
            - Can occur on first exposure (no sensitisation required)
- Shock
    - Definition
        - A state of cellular and tissue hypoxia due to inadequate tissue perfusion resulting in end-organ dysfunction
    - Types
        - Cardiogenic (pump failure)
            - Myopathic (AMI, myocarditis)
            - Arrhythmogenic
            - Structural (acute valvular rupture)
        - Obstructive (outflow failure)
            - Vascular (massive PE)
            - Cardiac tamponade
            - Tension pneumothorax
        - Hypovolaemic (inadequate volume to maintain perfusion)
            - Haemorrhage, burns, third space losses
        - Distributive (vasodilation → inadequate perfusion)
            - Anaphylaxis
            - Sepsis
            - Inflammatory/SIRS (burns, pancreatitis)
            - Neurogenic (loss of vascular tone) (spinal cord injury, TBI)
            - Toxic
    - Stages
        - Compensatory
            - BP maintained via increased HR, SV and vasoconstriction
                - Na and H2O retention
        - Progressive
            - Drop in BP despite compensatory mechanisms
            - Decreased urine output, changes in mental state, hypotension, tachycardia
        - Refractory
            - Ischaemia of vital organs → hypoxia, hypercapnia, lactic acidosis
                - Membrane permeability leads to release of K+ ions, lysosomal enzymes, free O2 radicals → further compromise
    - Which organs are affected
        - Reversibility of organ dysfunction depends on the organ, severity and duration of shock and the physical reserve of the patient (health, youth)
            - Kidney → AKI (most commonly ATN) - oliguria, rising serum Cr, fluid overload
            - Heart → angina, AMI
            - Brain → confusion, watershed infarcts
            - Lungs → ARDS (manage with mechanical ventilation (low VT and high PEEP)
            - Gut → epithelial compromise and transmural passage of bacteria and toxic absorption
            - DIC → thrombocytopaenia and coagulation abnormalities (prolonged INR and aPTT)
                - Many causes (endotoxin release, microvascular damage and tissue factor release which triggers the coagulation cascade (dysregulation of clotting and fibrinolysis)
            - Adrenal insufficiency may be seen in septic shock
- Septic shock
    - Definition
        - Sepsis-induced hypotension which persists despite fluid resuscitation
        - Progression from SIRS → sepsis (bacteraemia) → septic shock → multiple organ dysfunction
            - SIRS (at least 2 of the following)
                - Abnormal body temperature (<36 or > 38)
                - Tachycardia > 90
                - Tachypnoea > 20, or PaCO2 < 32
                - Abnormal WBC (>12 000 or < 4 000)
            - Sepsis = SIRS + confirmed or suspected infection
            - Severe sepsis
                - Sepsis + signs of end organ damage
                - Hypotension (<90)
                - Lactate > 4mmol
            - Septic shock
                - Severe sepsis with PERSISTENT signs of end organ damage, hypotension, elevated lactate
    - Pathophysiology
        - Initiation of immune response
            - Pathogen associated molecular patterns (PAMPs) or damage-associated (DAMPs) which activate toll-like receptors
            - Toxins
                - Lipopolysaccharide on Gram-negative bacteria
                    - Stimulates IL-1 and TNF-a production
                - Toxic shock syndrome toxin (S. aureus) → binds MHC II and TCR
                - Pyrogenic exotoxins (S. pyogenes)
        - Systemic release of inflammatory mediators by leukocytes (IL-1, TNF-a) → production of secondary mediators (NO)
            - Arteriolar vasodilation → decreased TPR and BP
            - Venous vasodilation → decreased preload and CO
            - Results in compensatory response (increased HR and contractility) but can lead to impaired organ perfusion if persistent
    - Investigative approach to septic shock
        - Clinical diagnosis
            - Supported strongly by confirmed source of infection (positive blood cultures)
        - Principal diagnostic investigation - confirm sepsis
            - Bedside
                - Blood gas (lactate) and acidosis
            - Bloods
                - 2 sets of blood culture (aerobic and anaerobic) from two different sites
                - FBC (leukocytosis, thrombocytopaenia (DIC)
                - Signs of end organ dysfunction
                    - UEC, LFT
                    - Coagulation studies (aPTT, PT)
                - BSL (likely elevated due to stress response)
        - Septic screen for source of infection
            - Urinalysis
            - CXR and sputum MCS
            - Swab MCS of wounds and lines
            - Lumbar puncture (meningitis)
            - Stool MCS and ova, cysts, parasites
            - Abscess drain and MCS
    - Empirical treatment for fever of unknown origin
        - Supportive care (fluid and electrolyte replacement, simple analgesics and anti-pyretics)
        - Collect specimens for investigation prior to sensitivity results
            - Note: culture-negative in 50%
        - Give empirical antibiotics
            - Unknown source - community acquired
                - Gentamicin (4-7mg/kg/daily) IV for Gram-negative cover
                    - Reassess situation and monitor if > 48h (third dose)
                - Flucloxacillin (2g IV Q4h) for Gram-positive cover
                    - If penicillin-sensitive, use cephalosporin (cefazolin 2g QID)
                    - If sensitive to both, use vancomycin
            - Consider
                - Metronidazole (500mg IV BD) for anaerobic cover (e.g. GIT involvement)
                - Ceftriazone (2g IV) (can cross BBB for N. meningitidis)
                - Meropenem (for multi-drug resistant Gram-negatives)
            - Unknown source - hospital acquired
                - Piperacillin + tazobactam
                - Vancomycin (risk of MRSA)
                    - If resistant - daptomycin, linezolid
                - For Pseudomonas
                    - Ceftazidime, cefepime
                    - Piperacillin + tazobactam
                    - Ciprofloxacin
                - for MDRE
                    - Meropenem
        - Risk factors for fungal sepsis
            - Recent surgery
            - Parenteral nutrition
            - Prolonged antimicrobial treatment
            - Prolonged hospitalisation (e.g. ICU)
            - Immunosuppression (chemotherapy, transplant, chronic liver or renal failure, diabetes)
- Interpret ABG and UEC
    
    ![paste-f26060e7ca925032ab49912e840f0418db8578a6.jpg](Anaphylaxis%20and%20Shock%201300acf2446a8189a6deea617f20d5c4/paste-f26060e7ca925032ab49912e840f0418db8578a6.jpg)
    
    - ABG
        - Acidosis with high PaCO2 and low HCO3
            - Mixed respiratory and metabolic acidosis
                - Airway obstruction → type 2 respiratory failure (hypercapnia)
                - Hypoperfusion of peripheral tissue (increased lactate → MA)
    - UEC
        - Low bicarbonate but otherwise WNL
        - Aware of AKI given sepsis and hypoperfusion
    

### Memorandum: Anaphylaxis (Pharm)

*A patient present with a bee sting. He had been stung before but had only a mild response. He now presents with tachycardia, tachypnoea, pallor, drowsiness, angioedema and a biphasic stridor.*

- Differential diagnosis
    - Anaphylaxis
    - Severe asthma attack
    - Non-IgE mediated reaction (anaphylactoid)
    - Foreign body aspiration
    - Other causes of shock
        - Cardiogenic (ACS)
        - Obstructive (tamponade, tension pneumothorax)
        - Septic
        - Hypovolaemic
        - Neurogenic
- Follow-up management?
    - Antihistamines (H1 antagonist) to relieve itch and urticaria
    - Corticosteroids (to cover biphasic reaction - evidence is mixed)
    - Prescription of at least one adrenaline autoinjector
    - Development of anaphylaxis action plan and provide written materials
    - Referral to allergy specialist
- Can adrenaline be given IV
    - IM adrenaline preferred due to ease of administration, controlled release and fewer side effects
        - IV adrenaline can be administered if inadequate response or clinical deterioration
        - Requires careful continuous monitoring with trained staff
    - Dose: 1mL of 1:1000 adrenaline in 1L of normal saline
    - Side effects: anxiety, palpitations, arrhythmias, severe hypertension
- Receptor specificity of adrenaline, noradrenaline
    - Adrenaline in anaphylaxis
        - Adrenaline has greater affinity for beta-adrenergic receptors (bronchodilators) → indicated in anaphylaxis
            - Stronger B2 effect than NA
    - Noradrenaline in septic shock
        - Noradrenaline has greater affinity for alpha-adrenergic receptors (vasoconstrictors) → indicated in septic shock
    - Dobutamine is used for inotropy and cardiac resuscitation (predominantly B1 selective)
        - B1 > B2 > a

Ananphylaxis

Anaphylactoid reaction

Anaphylactic shock (distributive shock)

Shock types:  cardiogenic, hypovolaemic, obstructive, distributive (septic, anaphylactic, neurogenic)

shock pathophysiology 

Complication = refractory shock 

Acid-Base disorder

acidosis vs acidaemia (process vs effect)

anion gap = unmeasured anions - unmeasured cations = 
Na + K - HCO3 - Cl

is there an excess? → if >12-16 ⇒ YES = HAGMA

Management

remove allergen/trigger 

adrenaline IM 1:1000 every 5 mins ⇒ a, B1, B2 receptors 

correct hypoxaemia ⇒ Supp O2 

correct BP ⇒ IV fluid resus/IV bolus isotonic sol. (every 5-10mins)

if not bronchodilated suff → other options salbutamol

if severe stridor not corrected yet → adrenaline nebulised 

antihistamines, corticosteroids (methylprednisolone)

relevant Hx: 

PMHx = atopy 

recent exposures (meds/ingestions/contact)

time course of symptoms 

 

main manifestations: at least 2 of 5 for Clinical dx

upp resp 

lower resp 

cardiovasc

GIT

cutaneous 

 Labs: Serum Mast Cell Tryptase (MCT) supports dx 

urticaria → local vasodilation 

shock not always reversible → if severe enough → death

other severe complications → hypoperfusion to end organs

AUTOPSY findings:

kidney - ATN

heart - subendocardial necrosis 

brain - necrosis of watershed areas

lungs - hypoxaemia + VQ mismatch + grossly congested lungs w/ inflamm debris (not pneumonic but anaphylactic immune mediated inflamm response)

skin - purpura (more severe - gangrene)

adrenal - frank adrenal haemorrhage 

bacterial sepsis (most common, most treatable, highest mortality)

Bacteraemia vs Sepsis 

sepsis - systemic inflamm response syndrome with suspected microbial cause

bacteraemia = bacteria in blood meeting certain threshold in the culture 

pyrogenic exotoxins

epitopes

toxic shock syndrome 

SIRS